Novartis AG
$NVSHot on XNYSEGLP-1Trending
12Posts · 1D
12Authors
+500%Vs prior 1D
→Novartis reportedly raised its 2026 core operating income guidance to flat or low single-digit growth, offsetting a $1.9 billion write-down from a del-desiran trial setback. Q3 revenue rose 4% to $14.5 billion, driven by strong performance in priority brands like Kisqali.
Research →